
Opinion|Videos|December 23, 2024
Infection Prevention and Leveraging EHR for Bispecific Therapy Management
Key Takeaways
- Weekly dosing may provide consistent therapeutic levels, while biweekly dosing reduces hospital visits, affecting patient convenience and healthcare resource allocation.
- Formulary decisions should evaluate efficacy, safety profiles, cost-effectiveness, and integration potential into existing treatment regimens.
Panelists discuss insights on infection prevention protocols and electronic health record (EHR)–based toxicity management strategies for patients receiving bispecific antibody therapies in relapsed/refractory multiple myeloma (RRMM).
Advertisement
Episodes in this series

Video content above is prompted by the following
- What best practices can you share regarding preventing infection in patients receiving bispecific therapies in RRMM?
- How has your institution leveraged the electronic health record to assist with standardization and management of toxicities seen with bispecific therapies?
Advertisement
Advertisement
Advertisement
Trending on Pharmacy Times
1
State Pharmacy Boards Must Step Up Against Illegal Retatrutide
2
New CKD Outcome Set Tells Pharmacists What to Measure
3
The PBM Reform Clock Is Running to 2028—Here's What Independent Pharmacies Should Do
4
GLP-1s and the HCM–Sleep Apnea–Obesity Connection
5


































































































